MarketBeat
12 Nov 2025, 16:18 UTC · 45w ago
Verdict
Headline takes no side. We score GRDN +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Guardian Pharmacy Services raised its full-year 2025 revenue guidance to $1.43B–$1.45B and adjusted EBITDA to $104M–$106M.
More positive than 99% of claims this week
The company reported Q3 revenue of $377 million and EPS of 25 cents, both exceeding analyst expectations.
So whatAn earnings beat across the board validates current valuation and often triggers immediate positive momentum in small-cap stocks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
Year-over-year revenue grew 20%, supported by a 13% increase in the total number of residents served.
So whatGrowth in the core customer metric (residents served) indicates expanding market share and organic demand for the company's services.
More positive than 87% of claims this week
Institutions have been net buyers of the stock, adding approximately $142 million in shares over the last twelve months.
More positive than 79% of claims this week
Seven insiders sold approximately $235 million worth of shares during the second quarter of 2025.
More negative than 77% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company reported better-than-expected earnings, exceeded revenue and EPS estimates, and raised its full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+32.1%
Price agrees with the score
$41.29 vs $31.25 close before publication (Nov 11) · not market-adjusted
GRDN chart →
